Evommune, Inc.
evommune.comWhat Do They Do?
Develops drug candidates for people with chronic inflammatory diseases, including chronic urticaria, atopic dermatitis and ulcerative colitis.
10-K for FY2025, filed Mar 5, 2026
How Do They Make Money?
Receives license fees from partners for rights to develop or commercialize drug candidates, plus development and sales milestone payments and royalties on future sales. Upfront payments follow contract schedules; milestones depend on contract events, and royalties are tied to licensees’ sales.
10-K for FY2025, filed Mar 5, 2026The terms of the Company’s license agreements typically may include payment to the Company of one or more of the following: non-refundable…View ↗
Up-front License Fees: If a license is determined to be distinct from the other performance obligations identified in the arrangement, the…View ↗
Milestone Payments: At the inception of an agreement that includes research and development milestone payments, the Company evaluates…View ↗
Royalties: If the Company is entitled to receive sales-based royalties from its licensees, including milestone payments based on the level…View ↗
The Company receives payments from its licensees based on schedules established in each contract. Upfront payments and fees are recorded as…View ↗
$13M
-
10-K for FY2025, filed Mar 5, 2026
$13M ↗
Who Are Their Customers?
License partners obtain rights to develop and commercialize candidates; Maruho holds an exclusive license to EVO756 in Japan.
10-K for FY2025, filed Mar 5, 2026
Do Revenues Turn Into Profits?
No. It lost $68.9M in FY2025.
10-K for FY2025, filed Mar 5, 2026
−$81.1MView ↗
10-K for FY2025, filed Mar 5, 2026
−$68.9MView ↗
10-K for FY2025, filed Mar 5, 2026
−$76.7MView ↗
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 6, 2026
−$32.2MView ↗
- ▲ +138% (Loss)
- vs −$13.6M in Q2 FY2025
-
Sep 8, 2026
EVO756 trial misses key measures; Evommune stops atopic dermatitis development
EVO301 advances as the lead atopic dermatitis program; its Phase 2b trial is planned for mid-2027.
Sources
8-K, filed Sep 9, 2026
“This trial did not deliver the outcome we and the AD community were hoping for,” said Luis Peña, President and Chief Executive Officer at…View ↗
-
Jun 29, 2026
EVO756 trial misses its main measure; Evommune stops chronic urticaria development
The study missed its main measure at every dose; Evommune will stop developing EVO756 for chronic spontaneous urticaria.
Sources
8-K, filed Jun 29, 2026
On June 29, 2026, the Company issued a press release announcing top-line results from its randomized, double-blind, placebo controlled…View ↗
Loading...
